Experts agree kratom and 7-OH need regulation, split on approach

STAT reports that experts concur kratom and its potent 7-OH derivatives require regulatory oversight, but disagree on the mechanism—whether to classify as dietary supplements, controlled substances, or a novel regulatory category. The emergence of high-concentration 7-OH products has intensified the debate, though no policy change has been enacted. This matters as it signals a potential shift in US drug policy that could affect consumer access and industry structure.